
Antisense and RNAi Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Technology (Antisense RNA and RNA Interference); By Route of Administration; By Application; By Region; Segment Forecast, 2024 - 2032
Description
Antisense and RNAi Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Technology (Antisense RNA and RNA Interference); By Route of Administration; By Application; By Region; Segment Forecast, 2024 - 2032
The global antisense and RNAi therapeutics market size is expected to reach USD 18.43 billion by 2032, according to a new study by Polaris Market Research. The report “Antisense and RNAi Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Technology (Antisense RNA and RNA Interference); By Route of Administration; By Application; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The global market for antisense and RNAi therapeutics has seen significant growth due to advancements in RNA-based drug development and improved understanding of disease mechanisms. These technologies are now being explored for new indications beyond their current uses, with many pipeline drugs targeting conditions with limited treatment options. Neurodegenerative disorders, such as Alzheimer's and Huntington's, are particularly challenging to treat, but emerging research suggests that RNA interference could offer new possibilities for addressing these conditions.
The expanding trend of multidisciplinary development approaches is having a substantial impact on the global market for antisense and RNAi therapies. Traditionally, preclinical and clinical research, regulatory affairs, and discovery were all conducted in distinct silos during the drug development process. Currently, nevertheless, there is a movement toward more integrated, interdisciplinary models that combine several fields of knowledge throughout the whole drug development life cycle.
RNAi and antisense medicines, which pose special technical obstacles, are benefiting from this comprehensive, cooperative approach. These nucleic acid-based medications necessitate input from a broad range of scientific disciplines, including molecular biology, biochemistry, pharmacology, and clinical medicine, due to their very mechanism of action. These specialist skill sets can work in multidisciplinary teams to progress antisense and RNAi candidates more efficiently as a group.
Untapped emerging markets offer significant growth opportunities for the global antisense and RNAi therapeutics market. Many developing countries have large numbers of patients suffering from life-threatening diseases, but they face limited or unavailable treatment options due to poor healthcare infrastructure and lack of access. Antisense and RNAi therapeutics have the potential to greatly improve patient outcomes in these countries by providing targeted treatments that are cost-effective and have fewer side effects than traditional drugs. This could expand access to essential medicines and facilitate the development of affordable new therapies for major diseases such as cancer, cardiovascular diseases, and hepatitis C, which have high mortality rates in these regions. Addressing the substantial unmet medical needs of underserved populations in these regions could be a driving force for market growth.
Antisense and RNAi Therapeutics Market Report Highlights
The antisense RNA segment dominated the market in 2023, driven by conducting tests on it to regulate various conditions.
The intrathecal injections segment led the market in 2023 and is expected to maintain its dominance due to its application in pain management and introduction of medications to fight particular infections.
North America holds a significant revenue share in the global antisense and RNAi therapeutics market, driven by major biopharmaceutical companies and heavy investment made by them in activities such as research and development.
The global key market players include Alynylam Pharmaceuticals, Inc., Arbutus Biopharma, Benitec Biopharma, Inc., GSK plc, Ionois Pharmaceuticals, Inc., Olix Pharmaceuticals, and Sanofi.
Polaris Market Research has segmented the Antisense and RNAi therapeutics market report based on technology, route of administration, application, and region:
Antisense and RNAi therapeutics, Technology Outlook (Revenue - USD Billion, 2019 - 2032)
Antisense RNA
RNA Interference
Others
Antisense and RNAi therapeutics, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)
Intrathecal Injections
Subcutaneous Injections
Intravenous Injections
Other Delivery Methods
Antisense and RNAi therapeutics, Application Outlook (Revenue - USD Billion, 2019 - 2032)
Neurodegenerative Disorders
Genetic Disease
Cancer
Cardiometabolic & Renal Disorders
Infectious Disease
Skin Disorders
Respiratory Disorders
Ocular Disorders
Antisense and RNAi therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
115 Pages
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. Global Antisense and RNAi Therapeutics Market Insights
- 4.1. Antisense and RNAi Therapeutics Market – Application Snapshot
- 4.2. Antisense and RNAi Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising focus on orphan and rare indications
- 4.2.1.2. Advancement in methods of delivering drugs
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Challenges associated with the delivery of RNA Therapeutics
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Antisense and RNAi Therapeutics Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
- 5. Global Antisense and RNAi Therapeutics Market, by Route of Administration
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 5.3. Intrathecal Injections
- 5.3.1. Global Antisense and RNAi Therapeutics Market, by Intrathecal Injections, by Region, 2019-2032 (USD Billion)
- 5.4. Subcutaneous Injections
- 5.4.1. Global Antisense and RNAi Therapeutics Market, by Subcutaneous Injections, by Region, 2019-2032 (USD Billion)
- 5.5. Intravenous Injections
- 5.5.1. Global Antisense and RNAi Therapeutics Market, by Intravenous Injections, by Region, 2019-2032 (USD Billion)
- 5.6. Other Delivery Methods
- 5.6.1. Global Antisense and RNAi Therapeutics Market, by Other Delivery Methods, by Region, 2019-2032 (USD Billion)
- 6. Global Antisense and RNAi Therapeutics Market, by Technology
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 6.3. Antisense RNA
- 6.3.1. Global Antisense and RNAi Therapeutics Market, by Antisense RNA, by Region, 2019-2032 (USD Billion)
- 6.4. RNA Interference
- 6.4.1. Global Antisense and RNAi Therapeutics Market, by RNA Interference, by Region, 2019-2032 (USD Billion)
- 6.5. Others
- 6.5.1. Global Antisense and RNAi Therapeutics Market, by Others, by Region, 2019-2032 (USD Billion)
- 7. Global Antisense and RNAi Therapeutics Market, by Application
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 7.3. Neurodegenerative Disorders
- 7.3.1. Global Antisense and RNAi Therapeutics Market, by Neurodegenerative Disorders, By Region, 2019-2032 (USD Billion)
- 7.4. Genetic Disease
- 7.4.1. Global Antisense and RNAi Therapeutics Market, by Genetic Disease, By Region, 2019-2032 (USD Billion)
- 7.5. Cancer
- 7.5.1. Global Antisense and RNAi Therapeutics Market, by Cancer, By Region, 2019-2032 (USD Billion)
- 7.6. Cardiometabolic & Renal Disorders
- 7.6.1. Global Antisense and RNAi Therapeutics Market, by Cardiometabolic & Renal Disorders, By Region, 2019-2032 (USD Billion)
- 7.7. Infectious Disease
- 7.7.1. Global Antisense and RNAi Therapeutics Market, by Infectious Disease, By Region, 2019-2032 (USD Billion)
- 7.8. Skin Disorders
- 7.8.1. Global Antisense and RNAi Therapeutics Market, by Skin Disorders, By Region, 2019-2032 (USD Billion)
- 7.9. Respiratory Disorders
- 7.9.1. Global Antisense and RNAi Therapeutics Market, by Respiratory Disorders, By Region, 2019-2032 (USD Billion)
- 7.10. Ocular Disorders
- 7.10.1. Global Antisense and RNAi Therapeutics Market, by Ocular Disorders, By Region, 2019-2032 (USD Billion)
- 8. Global Antisense and RNAi Therapeutics Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Antisense and RNAi Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
- 8.3. Antisense and RNAi Therapeutics Market – North America
- 8.3.1. North America: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.3.2. North America: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.3.3. North America: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.3.4. Antisense and RNAi Therapeutics Market – U.S.
- 8.3.4.1. U.S.: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.3.4.2. U.S.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.3.4.3. U.S.: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.3.5. Antisense and RNAi Therapeutics Market – Canada
- 8.3.5.1. Canada: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.3.5.2. Canada.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.3.5.3. Canada: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.4. Antisense and RNAi Therapeutics Market – Europe
- 8.4.1. Europe: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.4.2. Europe.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.4.3. Europe: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.4.4. Antisense and RNAi Therapeutics Market – UK
- 8.4.4.1. UK: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.4.4.2. UK.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.4.4.3. UK: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.4.5. Antisense and RNAi Therapeutics Market – France
- 8.4.5.1. France: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.4.5.2. France.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.4.5.3. France: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.4.6. Antisense and RNAi Therapeutics Market – Germany
- 8.4.6.1. Germany: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.4.6.2. Germany.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.4.6.3. Germany: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.4.7. Antisense and RNAi Therapeutics Market – Italy
- 8.4.7.1. Italy: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.4.7.2. Italy.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.4.7.3. Italy: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.4.8. Antisense and RNAi Therapeutics Market – Spain
- 8.4.8.1. Spain: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.4.8.2. Spain.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.4.8.3. Spain: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.4.9. Antisense and RNAi Therapeutics Market – Netherlands
- 8.4.9.1. Netherlands: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.4.9.2. Netherlands.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.4.9.3. Netherlands: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.4.10. Antisense and RNAi Therapeutics Market – Russia
- 8.4.10.1. Russia: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.4.10.2. Russia.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.4.10.3. Russia: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.5. Antisense and RNAi Therapeutics Market – Asia Pacific
- 8.5.1. Asia Pacific: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.5.2. Asia Pacific.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.5.3. Asia Pacific: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.5.4. Antisense and RNAi Therapeutics Market – China
- 8.5.4.1. China: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.5.4.2. China.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.5.4.3. China: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.5.5. Antisense and RNAi Therapeutics Market – India
- 8.5.5.1. India: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.5.5.2. India.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.5.5.3. India: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.5.6. Antisense and RNAi Therapeutics Market – Malaysia
- 8.5.6.1. Malaysia: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.5.6.2. Malaysia.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.5.6.3. Malaysia: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.5.7. Antisense and RNAi Therapeutics Market – Japan
- 8.5.7.1. Japan: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.5.7.2. Japan.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.5.7.3. Japan: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.5.8. Antisense and RNAi Therapeutics Market – Indonesia
- 8.5.8.1. Indonesia: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.5.8.2. Indonesia.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.5.8.3. Indonesia: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.5.9. Antisense and RNAi Therapeutics Market – South Korea
- 8.5.9.1. South Korea: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.5.9.2. South Korea.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.5.9.3. South Korea: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.6. Antisense and RNAi Therapeutics Market – Middle East & Africa
- 8.6.1. Middle East & Africa: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.6.2. Middle East & Africa.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.6.3. Middle East & Africa: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.6.4. Antisense and RNAi Therapeutics Market – Saudi Arabia
- 8.6.4.1. Saudi Arabia: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.6.4.2. Saudi Arabia.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.6.4.3. Saudi Arabia: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.6.5. Antisense and RNAi Therapeutics Market – UAE
- 8.6.5.1. UAE: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.6.5.2. UAE.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.6.5.3. UAE: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.6.6. Antisense and RNAi Therapeutics Market – Israel
- 8.6.6.1. Israel: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.6.6.2. Israel.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.6.6.3. Israel: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.6.7. Antisense and RNAi Therapeutics Market – South Africa
- 8.6.7.1. South Africa: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.6.7.2. South Africa.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.6.7.3. South Africa: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.7. Antisense and RNAi Therapeutics Market – Latin America
- 8.7.1. Latin America: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.7.2. Latin America.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.7.3. Latin America: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.7.4. Antisense and RNAi Therapeutics Market – Mexico
- 8.7.4.1. Mexico: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.7.4.2. Mexico.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.7.4.3. Mexico: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.7.5. Antisense and RNAi Therapeutics Market – Brazil
- 8.7.5.1. Brazil: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.7.5.2. Brazil.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.7.5.3. Brazil: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 8.7.6. Antisense and RNAi Therapeutics Market – Argentina
- 8.7.6.1. Argentina: Antisense and RNAi Therapeutics Market, by Route of Administration, 2019-2032 (USD Billion)
- 8.7.6.2. Argentina.: Antisense and RNAi Therapeutics Market, by Application, 2019-2032 (USD Billion)
- 8.7.6.3. Argentina: Antisense and RNAi Therapeutics Market, by Technology, 2019-2032 (USD Billion)
- 9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
- 10. Company Profiles
- 10.1. Alnylam Pharmaceuticals, Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Arbutus Biopharma
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Benitec Biopharma Inc.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. GSK plc
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Ionis Pharmaceuticals, Inc
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Olix Pharmaceuticals, Inc
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Percheron Therapeutics Limited
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Sanofi
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Sarepta Therapeutics
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Silence Therapeutics
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.